Skip to main content

Research Repository

Advanced Search

All Outputs (46)

Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro (2017)
Journal Article
Adesanya, M. A., Maraveyas, A., & Madden, L. A. (2017). Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro. Blood Coagulation and Fibrinolysis, 28(5), 365-372. https://doi.org/10.1097/MBC.0000000000000607

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. Microvesicles associated with tissue factor (TF) may play a role in cancer-related venous thromboembolism; however, not much is known about their interaction with the tumour stroma, es... Read More about Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro.

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy (2016)
Journal Article
Broughton, L. J., Giuntini, F., Savoie, H., Bryden, F., Boyle, R. W., Maraveyas, A., & Madden, L. A. (2016). Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy. Journal of photochemistry and photobiology. B, Biology, 163, 374-384. https://doi.org/10.1016/j.jphotobiol.2016.09.001

Duramycin, through binding with phosphatidylethanolamine (PE), has been shown to be a selective molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring about specific cytotoxic damage to tumours through deliv... Read More about Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy.

Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release (2016)
Journal Article
Ettelaie, C., Collier, M. E., Featherby, S., Greenman, J., & Maraveyas, A. (2016). Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release. BBA - Molecular Cell Research, 1863(11), 2846-2857. https://doi.org/10.1016/j.bbamcr.2016.09.005

Restriction of tissue factor (TF) activity at the cell surface and TF release are critical for prevention of excessive coagulation. This study examined the regulation of TF dephosphorylation and its release through ubiquitination. A plasmid containin... Read More about Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release.

Duramycin-induced calcium release in cancer cells (2016)
Journal Article
Broughton, L. J., Crow, C., Madden, L. A., & Maraveyas, A. (2016). Duramycin-induced calcium release in cancer cells. Anti-cancer drugs, 27(3), 173-182. https://doi.org/10.1097/cad.0000000000000313

Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has shown potential to be an effective anti-tumour agent. However its mode of action in relation to tumour cells is not fully understood. Methods: PE expression on the surface... Read More about Duramycin-induced calcium release in cancer cells.

Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression (2016)
Journal Article
Ettelaie, C., Collier, M. E. W., Featherby, S., Benelhaj, N. E., Greenman, J., & Maraveyas, A. (2016). Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thrombosis journal, 14(2), Article ARTN 2. https://doi.org/10.1186/s12959-016-0075-3

Background Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear. Methods In this study the upregulation of TF re... Read More about Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression.

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients (2016)
Journal Article
Van der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monreal, M., …Klok, F. A. (2016). Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of thrombosis and haemostasis : JTH, 14(1), 105-113. https://doi.org/10.1111/jth.13172

Essentials: We performed a pooled analysis of 926 patients with cancer-associated incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a higher risk of major hemorrhage. Recurrence risk is comparable after subsegmental... Read More about Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (2015)
Journal Article
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., …Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The lancet oncology, 16(8), 967-978. https://doi.org/10.1016/S1470-2045%2815%2900139-4

© 2015 Valle et al. Open Access article distributed under the terms of CC BY. Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors... Read More about Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation (2015)
Journal Article
ElKeeb, A. M., Collier, M. E. W., Maraveyas, A., & Ettelaie, C. (2015). Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thrombosis and haemostasis, 114(2), 364-378. https://doi.org/10.1160/th14-09-0795

We previously reported that high levels of tissue factor (TF) can induce cellular apoptosis in endothelial. In this study, TF-mediated mechanisms of induction of apoptosis were explored. Endothelial cells were transfected to express wild-type TF. Add... Read More about Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation.

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control (2014)
Journal Article
Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., …Sebag-Montefiore, D. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 25(7), 1356-1362. https://doi.org/10.1093/annonc/mdu147

Background: In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival (OS). In rectal adenocarcinoma following neoadjuvant chemoradiation (CRT), we exam... Read More about Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures (2014)
Journal Article
Ettelaie, C., Collier, M., Maraveyas, A., & Ettelaie, R. (2014). Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. Journal of Extracellular Vesicles, 3(1), 1-14. https://doi.org/10.3402/jev.v3.23592

© 2014 Camille Ettelaie et al. Microvesicles were isolated from the conditioned media of 3 cell lines (MDA-MB-231, AsPC-1 and A375) by ultracentrifugation at a range of relative centrifugal forces, and the tissue factor (TF) protein and activity, mic... Read More about Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures.

Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles (2013)
Journal Article
Collier, M. E. W., Ettelaie, C., & Maraveyas, A. (2014). Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles. Thrombosis and haemostasis, 111(4), 647-655. https://doi.org/10.1160/TH13-09-0769

We previously reported that the incorporation of tissue factor (TF) into cell-derived microvesicles (MVs) is regulated by the phosphorylation of the cytoplasmic domain of TF. Since the cytoskeletal protein filamin-A is known to bind to the cytoplasmi... Read More about Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles.

Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity (2013)
Journal Article
Collier, M. E. W., Mah, P., Xiao, Y., Maraveyas, A., & Ettelaie, C. (2013). Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thrombosis and haemostasis, 110(5), 966-976. https://doi.org/10.1160/TH13-01-0055

In this study the uptake of tissue factor (TF)-positive microparticles by endothelial cells and the recycling of the TF component were examined. Human dermal blood endothelial cells (HDBEC) were incubated with microparticles derived from cancer cell... Read More about Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity.

p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles (2013)
Journal Article
Ettelaie, C., ElKeeb, A. M., Maraveyas, A., & Collier, M. E. W. (2013). p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles. BBA - Molecular Cell Research, 1833(3), 613-621. https://doi.org/10.1016/j.bbamcr.2012.11.010

We previously showed that the phosphorylation of Ser253 within the cytoplasmic domain of human tissue factor (TF) initiates the incorporation and release of this protein into cell-derived microparticles. Furthermore, subsequent phosphorylation of Ser... Read More about p38 alpha phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles.

Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro (2012)
Journal Article
Ettelaie, C., Collier, M. E. W., Mei, M. P., Xiao, Y. P., & Maraveyas, A. (2013). Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro. Thrombosis and haemostasis, 109(1), 61-71. https://doi.org/10.1160/TH12-05-0279

The role of tissue factor (TF)-containing microparticles in clot propagation has been established, but the ability of circulating microparticles to initiate coagulation has been disputed. However, TF-bearing microparticles, particularly endothelial-m... Read More about Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro.

The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study (2012)
Journal Article
Sheard, L., Prout, H., Dowding, D., Noble, S., Watt, I., Maraveyas, A., & Johnson, M. (2012). The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study. BMC medical ethics, 13(22), Article ARTN 22. https://doi.org/10.1186/1472-6939-13-22

Background: Cancer patients are at risk of developing blood clots in their veins - venous thromboembolism (VTE) - which often takes the form of a pulmonary embolism or deep vein thrombosis. The risk increases with advanced disease. Evidence based tre... Read More about The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study.

Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study (2012)
Journal Article
Johnson, M. J., Sheard, L., Maraveyas, A., Noble, S., Prout, H., Watt, I., & Dowding, D. (2012). Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study. BMC Medical Informatics and Decision Making, 12(75), https://doi.org/10.1186/1472-6947-12-75

Background: The treatment of cancer associated thrombosis (CAT) is well established, with level 1A evidence to support the recommendation of a low molecular weight heparin (LMWH) by daily injection for 3-6 months. However, registry data suggest compl... Read More about Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study.

Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., ElKeeb, A. M., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease, 1812(12), 1591-1600. https://doi.org/10.1016/j.bbadis.2011.09.007

Treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects. In this study, the influence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity in five cell lines from variou... Read More about Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB.

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer (2011)
Journal Article
Ettelaie, C., Gardiner, E., Maraveyas, A., Bozas, G., Fyfe, D., Lofts, F., …Wedgwood, K. (2012). Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer, 48(9), 1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017

Background: Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall pr... Read More about Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro (2011)
Journal Article
Ettelaie, C., Fountain, D., Collier, M. E. W., Beeby, E., Xiao, Y. P., & Maraveyas, A. (2011). Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro. Experimental and Therapeutic Medicine, 2(2), 363-367. https://doi.org/10.3892/etm.2011.211

Elevated expression of tissue factor (TF) has been associated with an increased risk of thrombosis in the majority of cancers. Moreover, treatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneficial effects that rea... Read More about Low molecular weight heparin suppresses tissue factor-mediated cancer cell invasion and migration in vitro.